Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksORPH.L Share News (ORPH)

  • There is currently no data for ORPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Open Orphan CEO Steps Down; Inks New Challenge Study Contract

Mon, 04th May 2020 14:35

(Alliance News) - Open Orphan PLC on Monday announced that Chief Executive Trevor Phillips will be standing down and said it has signed a new contract with a US biotechnology.

Shares in the pharmaceutical services firm were up 10% at 9.90 pence in London in afternoon trading.

Philips will stay in his role until June end but has departed the board with immediate effects. He joined hVIVO at the end of 2018 and led hVIVO's merger with Open Orphan. Executive Chair Cathal Friel will lead Open Orphan.

The new contract is for Open Orphan to provide a human challenge study in respiratory syncytial virus, a highly contagious viral disease and among the most common causes of pneumonia and bronchiolitis. Challenge studies purposefully expose healthy volunteers to an infectious disease.

The biotechnology company's name was not disclosed, though Open Orphan expects to receive around GBP3.5 million of revenue in 2020 from the study.

Open Orphan acquired Venn Life Sciences Holdings PLC in January, the same month its completed its merger with hVIVO PLC. The study will use the clinical research organisation services of hVIVO and Venn and will take place at hVIVO's London-based quarantine unit in the third quarter of 2020.

Friel said: "Firstly, I would like to thank Trevor for his help merging Open Orphan and hVIVO. Trevor had previously successfully right sized and focused hVIVO and our refreshed management team is now focused on delivering growth at a very exciting time for the company.

"The signing of this new GBP3.5 million contract with a US biotechnology company is further evidence of this exciting time as we successfully convert Open Orphan's pipeline of prospects into formal customer contracts. Open Orphan will be utilising its complementary in-house [clinical research organisation] services of hVIVO and Venn to deliver this contract. This contract demonstrates the Open Orphan and hVivo group's focus on building long term contracts with recurring revenues to deliver future profitability while ensuring rationalising the business and reduce costs."

By Anna Farley; annafarley@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
9 Mar 2021 14:31

IN BRIEF: Open Orphan wins new contract with Oxford BioTherapeutics

IN BRIEF: Open Orphan wins new contract with Oxford BioTherapeutics

Read more
9 Mar 2021 11:38

Open Orphan subsidiary awarded contract with Oxford BioTherapeutics

(Sharecast News) - Specialist pharmaceuticals contract research organisation Open Orphan announced on Tuesday that its subsidiary Venn Life Sciences had been awarded a contract for a study with clinical-stage oncology company Oxford BioTherapeutics.

Read more
17 Feb 2021 13:48

IN BRIEF: Open Orphan Covid Characterisation Study Gets Approval

IN BRIEF: Open Orphan Covid Characterisation Study Gets Approval

Read more
3 Feb 2021 16:28

Open Orphan opens new quarantine clinic in Whitechapel

(Sharecast News) - Pharmaceutical services contract research organisation (CRO) Open Orphan has opened a new quarantine clinic in east London, it announced on Wednesday.

Read more
3 Feb 2021 11:55

IN BRIEF: Open Orphan Launches New Quarantine Clinic In London

IN BRIEF: Open Orphan Launches New Quarantine Clinic In London

Read more
1 Feb 2021 13:20

Open Orphan renews contract with Carna Biosciences

(Sharecast News) - Pharmaceutical services clinical research organisation Open Orphan announced a further contract renewal with Carna Biosciences on Monday, extending its integrated drug development consultancy services with Open Orphan subsidiary Venn Life Sciences.

Read more
1 Feb 2021 11:54

IN BRIEF: Open Orphan Inks Contract Renewal With Carna Biosciences

IN BRIEF: Open Orphan Inks Contract Renewal With Carna Biosciences

Read more
20 Jan 2021 21:16

IN BRIEF: Open Orphan Opens Two New Volunteer Recruitment Centres

IN BRIEF: Open Orphan Opens Two New Volunteer Recruitment Centres

Read more
11 Jan 2021 15:56

Open Orphan confirms first volunteer dosing of needle-free Covid vaccine

(Sharecast News) - Specialist pharmaceutical services contract research organisation Open Orphan announced on Monday that the first volunteer had been dosed with the Codagenix needle-free intranasal Covid-19 vaccine, 'COVI-VAC'.

Read more
11 Jan 2021 11:45

Open Orphan Doses First Volunteer In Needle Free Covid Vaccine Trial

Open Orphan Doses First Volunteer In Needle Free Covid Vaccine Trial

Read more
6 Jan 2021 14:37

IN BRIEF: Open Orphan Inks Contract Renewal With Top-3 Pharma Client

IN BRIEF: Open Orphan Inks Contract Renewal With Top-3 Pharma Client

Read more
23 Dec 2020 19:50

UK TRADING UPDATE SUMMARY: Polarean And Amryt Get US FDA Boost

UK TRADING UPDATE SUMMARY: Polarean And Amryt Get US FDA Boost

Read more
22 Dec 2020 14:26

IN BRIEF: Open Orphan Pens Contract Extension With Major Client

IN BRIEF: Open Orphan Pens Contract Extension With Major Client

Read more
22 Dec 2020 10:44

Open Orphan renews contract with top-3 pharma client

(Sharecast News) - Pharmaceutical services contract research organisation Open Orphan announced a contract renewal on Tuesday, extending its consultancy services with an unnamed "major top-three global" pharmaceutical client to December 2021.

Read more
14 Dec 2020 22:04

UK TRADING UPDATE SUMMARY: Novacyt Unveils New Test For Mink Covid

UK TRADING UPDATE SUMMARY: Novacyt Unveils New Test For Mink Covid

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.